title: Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
authors.forename: Bei
authors.initials: B
authors.lastname: Xiong
authors.forename: XinYue
authors.initials: X
authors.lastname: Liu
authors.forename: Ping
authors.initials: P
authors.lastname: Zou
authors.forename: LiHua
authors.initials: L
authors.lastname: Fan
authors.forename: WanXin
authors.initials: W
authors.lastname: Chen
authors.forename: WeiMing
authors.initials: W
authors.lastname: Li
authors.forename: Lin
authors.initials: L
authors.lastname: Liu
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000648:ultrastructure*; D002899:Chromosomes, Human, Pair 9 / Q000648:ultrastructure*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D018365:Neoplasm, Residual; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide